Free Trial

Avalyn Pharma (NASDAQ:AVLN) Stock Gets Price Target Trim from Morgan Stanley

Avalyn Pharma logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Morgan Stanley cut Avalyn Pharma’s price target from $57 to $53 but maintained its Overweight rating; the new target implies 77.85% upside from the current share price.
  • Analyst views are broadly positive, with a consensus “Moderate Buy” rating and average price target of $59.20. Shares fell 1.6% to $29.80 in Monday trading.
  • Avalyn reported a quarterly loss of $0.67 per share, missing analysts’ $0.64 loss estimate.
  • Five stocks we like better than Avalyn Pharma.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) had its price target dropped by equities researchers at Morgan Stanley from $57.00 to $53.00 in a research report issued to clients and investors on Monday, Benzinga reports. The firm currently has an "overweight" rating on the stock. Morgan Stanley's price target would indicate a potential upside of 77.85% from the company's current price.

Other research analysts also recently issued reports about the company. Wall Street Zen raised Avalyn Pharma from a "sell" rating to a "hold" rating in a research note on Saturday. Raymond James Financial began coverage on Avalyn Pharma in a research report on Friday, October 2nd. They set an "outperform" rating and a $60.00 target price for the company. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of Avalyn Pharma in a report on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $59.20.

Get Our Latest Report on Avalyn Pharma

Avalyn Pharma Trading Down 1.6%

Avalyn Pharma stock traded down $0.48 during mid-day trading on Monday, hitting $29.80. 13,792 shares of the company's stock were exchanged, compared to its average volume of 340,556. The company has a debt-to-equity ratio of 0.04, a quick ratio of 25.76 and a current ratio of 25.76. The firm has a market capitalization of $1.33 billion and a PE ratio of -1.31. Avalyn Pharma has a 1-year low of $22.24 and a 1-year high of $40.17. The business has a 50 day moving average price of $28.66.

Avalyn Pharma (NASDAQ:AVLN - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.03). As a group, research analysts predict that Avalyn Pharma will post -3.83 EPS for the current fiscal year.

Insider Transactions at Avalyn Pharma

In other news, insider Fmr Llc sold 53,454 shares of the firm's stock in a transaction dated Tuesday, November 10th. The stock was sold at an average price of $30.21, for a total value of $1,614,845.34. Following the sale, the insider directly owned 2,056,081 shares of the company's stock, valued at approximately $62,114,207.01. This trade represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Hedge Funds Weigh In On Avalyn Pharma

Several large investors have recently made changes to their positions in AVLN. Montanova Capital LLC acquired a new stake in Avalyn Pharma in the 2nd quarter valued at approximately $82,402,000. Braidwell LP bought a new position in Avalyn Pharma in the 2nd quarter worth approximately $26,382,000. State Street Corp acquired a new position in shares of Avalyn Pharma during the second quarter worth approximately $10,501,000. Bank of New York Mellon Corp acquired a new position in shares of Avalyn Pharma during the second quarter worth approximately $1,321,000. Finally, Profund Advisors LLC acquired a new position in shares of Avalyn Pharma during the third quarter worth approximately $668,000.

About Avalyn Pharma

(Get Free Report)

Avalyn Pharma is a clinical-stage biopharmaceutical company developing inhaled treatments for pulmonary fibrosis, including idiopathic pulmonary fibrosis and other progressive fibrotic lung diseases. Its approach is designed to deliver medicine directly to the lungs. The company's pipeline includes AP01, an investigational inhaled formulation of pirfenidone, and AP02, an investigational inhaled formulation of nintedanib. Both medicines are based on drugs used in oral form for pulmonary fibrosis, but Avalyn's inhaled candidates are being studied as potential alternatives to oral treatment.

Featured Articles

Analyst Recommendations for Avalyn Pharma (NASDAQ:AVLN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Avalyn Pharma Right Now?

Before you consider Avalyn Pharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avalyn Pharma wasn't on the list.

While Avalyn Pharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines